The Barclays Capital Global Healthcare Conference

March 13, 2012

Robert A. Cascella
President and CEO
Forward-Looking Statements

This presentation contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding: economic and market trends; financial or other information included herein based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the expected timing of regulatory submissions; and the Company’s outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could adversely affect the Company’s business and prospects are described in the Company’s filings with the Securities and Exchange Commission. This presentation is provided as part of an oral presentation and is qualified by such. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.
Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures “adjusted net income” and “adjusted earnings per share” (EPS). The Company defines its non-GAAP adjusted net income and adjusted EPS to exclude the non-cash amortization of intangible assets, other acquisition-related charges, such as change in contingent consideration, transaction costs, charges associated with the write-off of acquired in-process research and development and the write-up of acquired inventory to fair value, non-cash charges resulting from changes in GAAP, divestiture and restructuring charges, non-cash loss or exchange of convertible notes, and one-time, non-recurring, unusual or unanticipated charges, expenses or gains. Non-GAAP adjusted net income and non-GAAP adjusted EPS are not measures of operating performance under GAAP. We believe the use of these non-GAAP measures are useful to investors in comparing the results of operations in fiscal 2012 to the comparable period in fiscal 2011 by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash charges resulting from changes in GAAP, and litigation settlement, divestiture and restructuring. These measures also reflect how the company manages the business internally. When analyzing our operating performance, investors should not consider these non-GAAP measures as a substitute for net income and EPS prepared in accordance with GAAP.
Hologic is the leader in the large and growing women’s health market.
Breakdown of Q1 2012 Revenues of $472.7M

- **U.S. Revenues ~ 75%**
- **International Revenues ~ 25%**

- **45% Breast Health**
- **17% Surgical**
- **33% Diagnostics**
- **5% Skeletal**

- **59% Disposables**
- **17% Service**
- **24% Capital Equipment**

**Four Business Segments**

- **Disposables/Service ~ 76%**
- **Capital Equipment ~ 24%**
# Best in Class Products

<table>
<thead>
<tr>
<th>Screening</th>
<th>Biopsy Systems</th>
<th>Diagnosis</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>ThinPrep Pap Test Cervical Cancer Screening</td>
<td>MultiCare Stereotactic Breast Biopsy</td>
<td>Risk Assessment Fetal Fibronectin Testing</td>
<td>NovaSure Endometrial Ablation</td>
</tr>
<tr>
<td>Cervista HPV Tests</td>
<td></td>
<td></td>
<td>MammoSite Radiation Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MyoSure Hysteroscopic Tissue Removal System</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Early Detection... Saves Lives*
Hologic’s Global Growth Initiative

1. Drive solid organic growth through market dominance with best-in-class technologies
2. Invest in R&D to produce a steady pace of innovative new products
3. Expand internationally, primarily in emerging markets
4. Complete value-enhancing tuck-in acquisitions
Hologic’s Global Growth Initiative

Key to Success...Continued Expansion

- 2010 Revenues of $1.7B
- New Products/Organic Growth
- Tuck-ins
- International Expansion
- 2015 Double-Digit Revenue Growth
Breast Health - Mammography

Hologic’s Flagship and Most Significant Near-Term Growth Driver

Leader in Breast Cancer Screening & Diagnosis
Digital Mammography

- Approx. $4 billion U.S. addressable market (total)
- Market dominance: ~65% of U.S. installed base
- High single digit revenue growth expected
- Substantial replacement cycle imminent
- Strong competitive advantages of 3D Dimensions
  - Clinical superiority
  - First-to-market with no near-term competition

Robust Service Offering
- Recurring revenue stream driven by system placements
Hologic’s Global Growth Initiative

3D Dimensions Tomosynthesis

Superior Next-Generation Digital Mammography

Superiority over 2D Digital Mammography

Improved Tissue Visualization and Detection

Lower Recall Rates

Approved by the FDA on February 11, 2011
U.S. and international commercialization fully underway
First-to-market
Substantial 3D Dimensions Opportunity

Dominant Share of U.S. Installed Base and a Growing Replacement Cycle

Fundamental Factors Key to Adoption of 3D Dimensions

#1: Ongoing Clinical Validation of the Technology

Oslo study
- Over 12,000 patients imaged
- Significant increase in cancer detection rates

FDA trial data - submitted for publication by Dr. Betty Rafferty, Mass General Hospital

#2: Competition Among Regional Imaging Providers for Local Market Share Dominance

#3: Permanent Code for 3D Dimensions Reimbursement
Diagnostics

Cervical Cancer Screening & Diagnosis

*ThinPrep Pap Test & Related Instrumentation*

- The global standard of care
- U.S. market share ~ 70+%
- Significant EBITDA contributor
- Growth opportunity OUS, especially in China and other emerging markets

**In combination with.....**
Molecular Diagnostics

A Significant Contributor to Global Diagnostics Segment Growth

HPV Screening & Diagnosis

*Cervista HPV HR and 16/18 Genotyping*

- Best-in-class technologies
- Leverages powerful ThinPrep franchise with physician and lab sales infrastructure

HTA and MTA Lab Automation Technology

- Serves high, mid and low volume lab segments
- Recent approvals in U.S., Europe and China
- Developing full menu of sexually transmitted disease (STD) tests: CT/NG and Trichomonas
**Abnormal Uterine Bleeding**

*NovaSure*

- Clear leader with 60-65% share of a $1B+ global market opportunity
- Standard of care
- U.S. DTC campaign driving awareness & utilization

**Uterine Fibroids and Polyps**

*MyoSure*

- Double-digit annual growth expected
- Superior, minimally-invasive technology
- Maintains uterine form and function
MyoSure Hysteroscopic Tissue Removal System

Innovative technology
• Minimally-invasive technology to remove fibroids and polyps

Estimated Future U.S. Market: $300–$400M Growing Est. 20%+ Yearly

Women Suffering from Symptomatic Type 1-2 Fibroids and Polyps Treatable with MyoSure
U.S. Women Actively-Seeking Treatment and Curable if Used MyoSure
Hysteroscopic Morcellations
Hysterecomies for Type 1-2 Fibroids and Polyps

Large Market Opportunity Showing Early Signs of High Growth
A Global Opportunity

Global Sales and Service Network

460+ U.S. reps
The largest, dedicated U.S.-based women's healthcare sales force across multiple channels

550+ international reps/distributors
An international network of 400+ sales reps and 150+ distributors in > 150 countries

650+ service personnel
Established worldwide service and customer support infrastructure
R&D Investment Drives Innovation

Steady Pace of New Product Approvals in Last 12 Months

U.S. FDA approvals
- Dimensions 3D Tomosynthesis (PMA)
- Cervista HPV High-Throughput Automation (PMA)
- Sentinelle Prostate coils (510k)
- Sentinelle 16-channel breast coils (510k)
- Trident Specimen Radiography system (510k)

International approvals
- Serenity digital mammography system (SFDA – China)
- Cervista HPV HR test (SFDA – China)
- C-View (CE Marking)
- Cervista MTA Medium-Throughput Automation (CE Marking)
Building Emerging Market Presence

2011 Investments and Recent Progress

Two recent acquisitions in 2011 increased our footprint in China
- TCT Medical – Market leading distributor of ThinPrep
- Healthcome – Manufacturer of low-cost mammography systems
- China will be major growth driver over the next five years
  - Improving healthcare standards for the emerging middle class
  - Hospital construction fueling demand for capital equipment
- $300 million annual potential revenue opportunity

Enhancing the infrastructure to sell Hologic’s existing and newly-approved products
- ThinPrep (existing)
- Cervista HPV HR test, NovaSure and Serenity Digital Mammography system (recently approved)
- Utilizing the model to further expand into other emerging markets
Hologic’s Global Growth Initiative

Hologic Acquires TCT Medical (China) on June 1, 2011

Leading Liquid-Based Pap Distributor in China (50% Market Share)

Deal

- $100M at time of signing, $35M in one year and earn out
- >300 direct salespeople
- FY11 sales (for 4 months) approximately $10M

Rationale

- Access to growing market
- Established channel for new products
- Double-digit revenue and earnings growth
- Accretive transaction
Deal

- Aggregate amount up to $15.2 million

Rationale

- Creates platform for launching low-cost digital mammography product
- Leverages strong mammography relationships in breast screening market that is just taking off
- Provides low-cost development and manufacturing base to serve emerging markets
- Neutral transaction in FY11
Hologic’s Global Growth Initiative

Digital Mammography Opportunity in Emerging Markets

• SFDA (China) approval of Serenity, December 2011, ahead of expectations
• Targets entry-level mammography market
  – Superior performance to competitive offerings
• Incorporates the same selenium detector used in higher end FFDM
• Initial launch underway in China
• Future opportunity: price-sensitive emerging markets of Asia, Latin America, Eastern Europe and eventually India
## FY 2012 Guidance*

**Quarter Ending March 24, 2012 and Year Ending September 29, 2012**

<table>
<thead>
<tr>
<th></th>
<th>Non-GAAP**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY 2012</td>
</tr>
<tr>
<td></td>
<td>(Guidance)*</td>
</tr>
<tr>
<td>$, millions</td>
<td></td>
</tr>
<tr>
<td>(except EPS)</td>
<td></td>
</tr>
<tr>
<td>Revenues</td>
<td>$1,900 – $1,925</td>
</tr>
<tr>
<td>Gross Margins</td>
<td>61.5% – 62.5%</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>$590 – $600</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>$42</td>
</tr>
<tr>
<td>Diluted EPS</td>
<td>$1.36 – $1.38</td>
</tr>
<tr>
<td>Free Cash Flows</td>
<td>$400 - 425</td>
</tr>
</tbody>
</table>

* As provided on January 30, 2012.
** See the definition of non-GAAP financial measures on page 3 of this presentation.
Summary

Best-in-class Technologies

Market Share Dominance

Global Sales and Service Network

Strategic Plan:
- New Products
- International Expansion
- Tuck-in Acquisitions

Strong, Predictable Financial Performance
HOLOGIC’S Global Growth Initiative